HAP Trading’s Protagonist Therapeutics PTGX Stock Holding History

HAP Trading’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-31,600	Closed	-$54K	–	2798
2021 Q3	$54K	Buy	+31,600	New	+$1.35M	﹤0.01%	1483

Other funds holding PTGX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

HAP Trading's PTGX Position: Q1 2022 in Review

HAP Trading sold out of Protagonist Therapeutics (PTGX) in Q1 2022, closing a stake of 19,166 shares — an estimated $655K sold.

HAP Trading first reported a position in PTGX in Q3 2021 and held it in 2 quarters. The position peaked at $655K in Q4 2021. 140 funds tracked by Wall St. Rank hold PTGX as of Q1 2022.

HAP Trading reported no remaining Protagonist Therapeutics position as of Q1 2022 after selling out during the quarter.
HAP Trading sold 19,166 Protagonist Therapeutics shares in Q1 2022, an estimated $655K.
HAP Trading first reported a position in Protagonist Therapeutics in Q3 2021 and held it in 2 quarters.
HAP Trading's Protagonist Therapeutics position peaked at $655K in Q4 2021.
140 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2022.

Based on HAP Trading's 13F filing for Q1 2022, filed 12 May 2022.